Axogen (AXGN) CMO sells 4,000 shares around $43 per share

Rhea-AI Filing Summary

Axogen, Inc. Chief Marketing Officer Jens Kemp reported an open-market sale of 4,000 shares of Axogen common stock. The weighted average sale price was $43.4403 per share, with individual trades executed between $43.44 and $43.45 per share. Following these transactions, Kemp directly owns 72,451 shares of Axogen common stock.

Insider Trade Summary

Net Seller: 4,000 shares ($173,761)

Net Sell 1 txn

Insider Kemp Jens

Role Chief Marketing Officer

Sold 4,000 shs ($174K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,000	$43.4403	$174K

Holdings After Transaction: Common Stock — 72,451 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 4,000 shares Weighted average sale price: $43.4403 per share Price range of sales: $43.44–$43.45 per share +1 more

4 metrics

Shares sold 4,000 shares Open-market sale of Axogen common stock

Weighted average sale price $43.4403 per share Average price for the 4,000 shares sold

Price range of sales $43.44–$43.45 per share Range of individual trade prices

Shares owned after transaction 72,451 shares Direct holdings of Jens Kemp following sale

Key Terms

open-market sale, weighted average sale price, Common Stock

3 terms

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

weighted average sale price financial

"The reported price in Column 4 is a weighted average sale price."

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kemp Jens

(Last) (First) (Middle)

13631 PROGRESS BLVD.,

SUITE 400

(Street)

ALACHUA FLORIDA 32615

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Axogen, Inc. [ AXGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Marketing Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/07/2026	05/07/2026	S		4,000	D	$43.4403(1)	72,451	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $43.44 to $43.45 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Remarks:

	Marc Began, as attorney-in-fact for Jens Kemp	05/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Axogen (AXGN) report for Jens Kemp?

Axogen reported that Chief Marketing Officer Jens Kemp sold 4,000 shares of Axogen common stock in an open-market transaction. The filing shows this was a routine Form 4 disclosure of insider trading activity with details on price and remaining ownership.

How many Axogen (AXGN) shares did Jens Kemp sell and at what price?

Jens Kemp sold 4,000 shares of Axogen common stock at a weighted average price of $43.4403 per share. A footnote explains the shares were sold in multiple trades within a narrow range between $43.44 and $43.45 per share.

How many Axogen (AXGN) shares does Jens Kemp hold after this Form 4 sale?

After the reported sale, Jens Kemp directly holds 72,451 shares of Axogen common stock. This figure reflects his position immediately following the 4,000-share open-market sale disclosed in the Form 4 insider trading report.

What does the weighted average sale price mean in the Axogen (AXGN) Form 4?

The weighted average sale price of $43.4403 reflects the combined average of multiple trades making up the 4,000 shares sold. Actual transaction prices ranged from $43.44 to $43.45, as disclosed in the footnote to the Form 4 filing.

Was the Axogen (AXGN) Form 4 transaction by Jens Kemp direct or indirect ownership?

The Form 4 shows the transaction under direct ownership, indicated by the code "D" for nature of ownership. This means the 4,000 shares sold and the 72,451 shares remaining are held directly by Jens Kemp, not through an intermediary entity.

Did the Axogen (AXGN) Form 4 involve any derivative securities or option exercises?

No, the reported transaction involved only non-derivative common stock. The filing lists no derivative transactions, and the derivativeSummary section is empty, indicating there were no option exercises, warrants, or other derivative activities disclosed in this Form 4.